Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials
Yıl: 2017 Cilt: 34 Sayı: 1 Sayfa Aralığı: 1 - 15 Metin Dili: İngilizce İndeks Tarihi: 20-03-2019
Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials
Öz: Objective: To evaluate the efficacy and safety of brivaracetam (BRV) as an add-on therapyfor people with drug-resistant epilepsy.Methods: Comprehensive literature search was done in PubMed, Cochrane Library and otherdatabases for clinical trials (CTs) investigating the efficacy of BRV in the treatment of drugresistant epilepsy. 5 CTs having 12 dose groups including 2,187 patients comparing BRV(1212 patients) to placebo (975 patients) are pooled in the present analysis. Subgroup,sensitivity and meta-regression analysis are also performed.Results: The pooled RD in favour of BRV over placebo for ≥50% seizure frequencyreduction was 13% and 3% for complete seizure freedom. The pooled RD for the proportionof patients withdrawn, withdrawn due to adverse events (AEs) and experienced with AEs wasin favour of placebo over BRV 3%, 1% and 5%, respectively. Meta-regression analysis wasdemonstrated no significant linear relationship to dose, but significant linear relationship totreatment duration.Conclusion: Meta-analysis provides evidence supporting BRV effectiveness as an add-ontreatment for drug-resistant epilepsy. However, results may not be generalizable due to thepooled trials were of relatively short duration, small sample size, heterogeneity and provideno evidence for the long-term efficacy of BRV.
Anahtar Kelime: Konular:
Epilepside Brivaracetam Ek Tedavisi : Randomize Kontrollü Çalışmalarda Kanıta Dayalı Metaanaliz ve Metaregresyon
Öz: Amaç: İlaca dirençli epilepsi hastalarında brivaracetam’ın (BRV) ek tedavi olarak etkinliğini ve güvenilirliğini değerlendirmek. Yöntem: BRV’nin ilaca dirençli epilepsi hastalarının tedavisinde etkinliğinin araştırılması için PubMed, Cochrane Kütüphanesi ve klinik çalışmalarla ilgili diğer bilgi bankalarından geniş kapsamlı literatür araştırılması yapıldı. Bulgular: Plaseboyla kıyaslandığında havuzlanmış risk farkı BRV lehine olup nöbet sıklığında % 50’den fazla azalma için % 13, tam nöbetsizlik için ise % 3 idi. Çalışmadan yan etkilere bağlı çekilen ve yan etki deneyimleyen hastaların oranı BRV ile kıyaslandığında plasebo lehine olup havuzlanmış risk farkı çalışmadan çekilen hastalar için sırasıyla % 3, % 1 ve % 5 idi. Meta regresyon analizi dozla ilgili anlamlı lineer ilişki göstermezken, tedavi süresiyle ilgili anlamlı lineer ilişki göstermiştir. Sonuç: Metaanaliz ilaca dirençli epilepsi hastalarında BRV’nin ek tedavide etkinliğini destekleyen kanıtlar sağlamaktadır. Ancak, sonuçlar çalışmaların kısa süreli olması , örneklem büyüklüğünün küçük olması, heterojen olması ve BRV’nin uzun dönemli etkinliği ile ilgili hiçbir kanıt sağlamaması nedeniyle genellenemez.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- World Health Organization. Epilepsy. Available from: http://www.who.int/mediacentre/factsheets/fs999/en /. Accessed on 10 September 2015.
- Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy andtolerability of adjunctive brivaracetam in adults with uncontrolled partial-onsetseizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54:89-97.
- Matagne A, Margineanu D-G, Kenda B, et al. Anti- convulsive and anti-epileptic properties of brivaracetam (ucb34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154:1662-1671.
- Pack AM. Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe Results from One Phase III Randomized Trial. Epilepsy Curr 2014;14:196-198.
- Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008;54:715-720.
- Gillard M, Fuks B, Leclercq K, et al. Binding characteristicsof brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011;664:36-44.
- Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004; 47:530-549.
- Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54. Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69:1027-1034.
- French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial- onset seizures: a randomized, controlled trial. Neurology2010;75:519-525.
- Werhahn KJ, Biton V, Johnson ME, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials [abstract no: p507]. Epilepsia 2010;51:150.
- Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007; 63:680-688.
- Sargentini-Maier ML, Espie ́ P, Coquette A, et al. Pharmacokinetics and metabolism of 14C- brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008;36:36-45.
- Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008;66:71-75.
- Nicolas JM, Chanteux H, Rosa M, et al. Effect of gemfibrozilon the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos 2012;40:1466-1472.
- Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol 2010;9:27-29.
- Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005;46:858-877.
- Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine,remacemide and zonisamide for drug-resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46:259-270.
- Higgins JPT, Green S (editors). Cochrane Handbookfor Systematic Reviews of Interventions
- Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011.
- Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
- Rotondi MA, Khobzi N. Vitamin A supplementation and neonatal mortality in the developing world: a meta-regression of cluster-randomized trials. Bull World Health Organ 2010;88:697-702.
- Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55:38-46.
- Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetamin adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47-56.
- Biton V, Berkovic SF, Abou-Khalil B, et al.Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57-66.
| APA | DASARI A, BANSAL D, GUDALA K (2017). Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. , 1 - 15. |
| Chicago | DASARI Anil,BANSAL Dipika,GUDALA Kapil Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. (2017): 1 - 15. |
| MLA | DASARI Anil,BANSAL Dipika,GUDALA Kapil Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. , 2017, ss.1 - 15. |
| AMA | DASARI A,BANSAL D,GUDALA K Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. . 2017; 1 - 15. |
| Vancouver | DASARI A,BANSAL D,GUDALA K Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. . 2017; 1 - 15. |
| IEEE | DASARI A,BANSAL D,GUDALA K "Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials." , ss.1 - 15, 2017. |
| ISNAD | DASARI, Anil vd. "Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials". (2017), 1-15. |
| APA | DASARI A, BANSAL D, GUDALA K (2017). Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. Journal of Neurological Sciences (Turkish), 34(1), 1 - 15. |
| Chicago | DASARI Anil,BANSAL Dipika,GUDALA Kapil Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. Journal of Neurological Sciences (Turkish) 34, no.1 (2017): 1 - 15. |
| MLA | DASARI Anil,BANSAL Dipika,GUDALA Kapil Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. Journal of Neurological Sciences (Turkish), vol.34, no.1, 2017, ss.1 - 15. |
| AMA | DASARI A,BANSAL D,GUDALA K Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. Journal of Neurological Sciences (Turkish). 2017; 34(1): 1 - 15. |
| Vancouver | DASARI A,BANSAL D,GUDALA K Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials. Journal of Neurological Sciences (Turkish). 2017; 34(1): 1 - 15. |
| IEEE | DASARI A,BANSAL D,GUDALA K "Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials." Journal of Neurological Sciences (Turkish), 34, ss.1 - 15, 2017. |
| ISNAD | DASARI, Anil vd. "Brivaracetam Add-on Therapy for Epileps y: Evidence Based Meta-analysis an d Meta- regression of Randomized Controlled Trials". Journal of Neurological Sciences (Turkish) 34/1 (2017), 1-15. |
